Just a further thought about Cavendish and innovation.

One of the things I have learned throughout my corporate life is that innovation and more importantly the adoption of innovations takes time and takes a certain breed of people, mindsets (ability and resources to take chances) and leadership.

A while back I started to realize that epigenetics is a new field in science...an area being pursued by innovative, new breed scientists.

Resverlogix is on the forefront of BET bromodomain epigenetic research and drug development and has demonstrated very powerful results with rvx-208 regarding a number of indications.

We know that in general BPs are not innovators. The FDA is very conservative and risk averse as it should be. The scientific community is very conservative.

The group of scientists that understand the idea of epigenetics at this stage is probably very small.

So my feeling, as I have posted before, is that one of the big challenges that RVX faces is getting recognition for how innovative and leading edge RVX is. Obviously, Eastern, NGN and Hepalink get it. I believe there are many retail investors that get it and are long but the broad market of potential investors are sitting on the side lines waiting for the BoM trial results.

Being accepted by Cavendish is a clear opportunity to gain credibility with a huge investment community that has the perfect objectives for Resverlogix - philanthropy, investing and innovation. These people are open to a drug that will help society.

The visibility achieved at this conference IMHO is very significant because of the kind of audience. These people have a broader societal objective, the money and the mindset to assess innovation and the potential of rvx-208 to fulfill unmet needs in CVD, CKD, diabetes, Alzheimer's and various orphan conditions.

Congratulations to Don and his team on this achievement.

Cheers

Toinv